Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

PURPOSE: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHOD...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Motzer, Robert J., Nosov, Dmitry, Eisen, Timothy, Bondarenko, Igor, Lesovoy, Vladimir, Lipatov, Oleg, Tomczak, Piotr, Lyulko, Oleksiy, Alyasova, Anna, Harza, Mihai, Kogan, Mikhail, Alekseev, Boris Y., Sternberg, Cora N., Szczylik, Cezary, Cella, David, Ivanescu, Cristina, Krivoshik, Andrew, Strahs, Andrew, Esteves, Brooke, Berkenblit, Anna, Hutson, Thomas E.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2013
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569677/
https://ncbi.nlm.nih.gov/pubmed/24019545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.4940
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы